Sanofi $SNY Shares Sold by American Century Companies Inc.

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

American Century Companies Inc. decreased its holdings in shares of Sanofi (NASDAQ:SNY - Free Report) by 11.2% during the first quarter, according to its most recent disclosure with the SEC. The fund owned 1,515,244 shares of the company's stock after selling 191,813 shares during the period. American Century Companies Inc. owned approximately 0.06% of Sanofi worth $84,035,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of the business. Bank of America Corp DE grew its stake in shares of Sanofi by 3.8% during the fourth quarter. Bank of America Corp DE now owns 12,017,140 shares of the company's stock worth $579,587,000 after acquiring an additional 441,637 shares during the last quarter. Price T Rowe Associates Inc. MD grew its stake in shares of Sanofi by 88.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 10,843,682 shares of the company's stock worth $522,991,000 after acquiring an additional 5,091,304 shares during the last quarter. Federated Hermes Inc. grew its stake in shares of Sanofi by 58.5% during the first quarter. Federated Hermes Inc. now owns 3,947,583 shares of the company's stock worth $218,933,000 after acquiring an additional 1,456,269 shares during the last quarter. Nuveen Asset Management LLC grew its stake in shares of Sanofi by 1.0% during the fourth quarter. Nuveen Asset Management LLC now owns 3,676,224 shares of the company's stock worth $177,304,000 after acquiring an additional 34,660 shares during the last quarter. Finally, Envestnet Asset Management Inc. grew its stake in shares of Sanofi by 6.9% during the first quarter. Envestnet Asset Management Inc. now owns 3,277,394 shares of the company's stock worth $181,764,000 after acquiring an additional 211,641 shares during the last quarter. Hedge funds and other institutional investors own 14.04% of the company's stock.

Sanofi Stock Performance

NASDAQ:SNY traded up $0.08 during trading hours on Thursday, reaching $50.61. The company had a trading volume of 1,491,271 shares, compared to its average volume of 2,567,537. Sanofi has a 1-year low of $44.73 and a 1-year high of $60.12. The firm has a market cap of $124.27 billion, a PE ratio of 12.17, a price-to-earnings-growth ratio of 1.20 and a beta of 0.48. The business's 50 day moving average price is $48.59 and its 200-day moving average price is $51.76. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.27 and a quick ratio of 0.94.

Sanofi (NASDAQ:SNY - Get Free Report) last announced its quarterly earnings results on Thursday, July 31st. The company reported $0.90 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.96 by ($0.06). Sanofi had a net margin of 21.47% and a return on equity of 16.86%. The company had revenue of $11.34 billion during the quarter, compared to analyst estimates of $9.91 billion. During the same period in the previous year, the firm posted $1.73 earnings per share. The company's revenue was down 7.0% compared to the same quarter last year. Research analysts forecast that Sanofi will post 4.36 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently commented on SNY shares. Deutsche Bank Aktiengesellschaft reiterated a "hold" rating on shares of Sanofi in a research report on Tuesday, August 5th. Morgan Stanley set a $56.00 target price on Sanofi in a research report on Monday, June 2nd. Hsbc Global Res upgraded Sanofi to a "strong-buy" rating in a research report on Monday, April 28th. JPMorgan Chase & Co. upgraded Sanofi from a "neutral" rating to an "overweight" rating in a research report on Friday, August 8th. Finally, Barclays reiterated an "overweight" rating on shares of Sanofi in a research report on Wednesday, July 2nd. Three research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus price target of $62.00.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.